Literature DB >> 21400914

[A nationwide survey concerning lung surgery for lung cancer associated with idiopathic interstitial pneumonia].

Atsushi Miyamoto1, Kazuma Kishi, Kunihiko Yoshimura.   

Abstract

Acute exacerbation (AE) of idiopathic interstitial pneumonia (IIP) is a near-fatal condition with especially high risk following lung surgery. We conducted a nationwide survey concerning prophylactic therapy to prevent possible AE following lung surgery in Japan. We sent a questionnaire concerning prophylactic therapy immediately before and after lung surgery to a total of 701 institutions, including specific questions about anesthesia. Some prophylactic medication was applied in 128 institutions (prophylactic group : P group). In contrast, no prophylactic therapy was utilized in the remaining 92 institutions (non-prophylactic group : N group). In 1 year, 744 operations were performed for lung cancer associated with IIP. In the P group, the prevalence of AE following surgery was 7.8%, and the mortality rate was 48.4%. In the N group, the prevalence was 9.6%, and the mortality rate was 32.2%. In 204 departments (92.7%), certain specific settings for ventilation or surgery were applied. In conclusion, it is necessary to further evaluate the feasibility of such prophylactic therapy, and standard guidelines should be established.

Entities:  

Mesh:

Year:  2011        PMID: 21400914

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  5 in total

1.  Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis.

Authors:  Yoshikane Yamauchi; Yotaro Izumi; Masanori Inoue; Hiroaki Sugiura; Taichiro Goto; Masaki Anraku; Takashi Ohtsuka; Mitsutomo Kohno; Kenzo Soejima; Hiroaki Nomori
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

2.  Early Detection of the Acute Exacerbation of Interstitial Pneumonia after the Surgical Resection of Lung Cancer by Planned Chest Computed Tomography.

Authors:  Kunihiro Oyama; Masato Kanzaki; Mitsuko Kondo; Hideyuki Maeda; Kei Sakamoto; Tamami Isaka; Jun Tamaoki; Takamasa Onuki
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2017-06-05

Review 3.  International consensus on severe lung cancer-the first edition.

Authors:  Chengzhi Zhou; Shiyue Li; Jun Liu; Qian Chu; Liyun Miao; Linbo Cai; Xiuyu Cai; Yu Chen; Fei Cui; Yuchao Dong; Wen Dong; Wenfeng Fang; Yong He; Weifeng Li; Min Li; Wenhua Liang; Gen Lin; Jie Lin; Xinqing Lin; Hongbing Liu; Ming Liu; Xinlin Mu; Yi Hu; Jie Hu; Yang Jin; Ziming Li; Yinyin Qin; Shengxiang Ren; Gengyun Sun; Yihong Shen; Chunxia Su; Kejing Tang; Lin Wu; Mengzhao Wang; Huijuan Wang; Kai Wang; Yuehong Wang; Ping Wang; Hongmei Wang; Qi Wang; Zhijie Wang; Xiaohong Xie; Zhanhong Xie; Xin Xu; Fei Xu; Meng Yang; Boyan Yang; Xiangjun Yi; Xiaoqun Ye; Feng Ye; Zongyang Yu; Dongsheng Yue; Bicheng Zhang; Jian Zhang; Jianqing Zhang; Xiaoju Zhang; Wei Zhang; Wei Zhao; Bo Zhu; Zhengfei Zhu; Wenzhao Zhong; Chunxue Bai; Liangan Chen; Baohui Han; Chengping Hu; Shun Lu; Weimin Li; Yong Song; Jie Wang; Caicun Zhou; Jianying Zhou; Yanbin Zhou; Yuichi Saito; Yoshinobu Ichiki; Hitoshi Igai; Satoshi Watanabe; Sara Bravaccini; Alfonso Fiorelli; Francesco Petrella; Takeo Nakada; Piergiorgio Solli; Nikolaos Tsoukalas; Yuki Kataoka; Taichiro Goto; Rossana Berardi; Jianxing He; Nanshan Zhong
Journal:  Transl Lung Cancer Res       Date:  2021-06

4.  Clarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy.

Authors:  Atsuya Takeda; Yuichiro Tsurugai; Naoko Sanuki; Tatsuji Enomoto; Masaharu Shinkai; Tomikazu Mizuno; Yousuke Aoki; Yohei Oku; Takeshi Akiba; Yu Hara; Etsuo Kunieda
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 5.  The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis.

Authors:  Akira Saito; Masafumi Horie; Patrick Micke; Takahide Nagase
Journal:  Int J Mol Sci       Date:  2018-11-15       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.